University of Montana

ScholarWorks at University of Montana
Biomedical and Pharmaceutical Sciences
Faculty Publications

Biomedical and Pharmaceutical Sciences

2-2021

Leucine Carboxyl Methyltransferase 1 Overexpression Protects
Against Cognitive and Electrophysiological Impairments in
Tg2576 APP Transgenic Mice
Madhumathi Gnanaprakash
Agnieszka Staniszewski
Hong Zhang
Rose Pitstick
Michael P. Kavanaugh

See next page for additional authors

Follow this and additional works at: https://scholarworks.umt.edu/biopharm_pubs
Part of the Medical Sciences Commons, and the Pharmacy and Pharmaceutical Sciences Commons

Let us know how access to this document benefits you.

Authors
Madhumathi Gnanaprakash, Agnieszka Staniszewski, Hong Zhang, Rose Pitstick, Michael P. Kavanaugh,
Ottavio Arancio, and Russell E. Nicholls

1813

Journal of Alzheimer’s Disease 79 (2021) 1813–1829
DOI 10.3233/JAD-200462
IOS Press

Leucine Carboxyl Methyltransferase 1
Overexpression Protects Against Cognitive
and Electrophysiological Impairments in
Tg2576 APP Transgenic Mice
Madhumathi Gnanaprakasha,b , Agnieszka Staniszewskia,b , Hong Zhanga,b , Rose Pitstickc ,
Michael P. Kavanaughc , Ottavio Arancioa,b,d and Russell E. Nichollsa,b,∗
a Department

of Pathology and Cell Biology, Columbia University, New York, NY, USA
Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York,
NY, USA
c McLaughlin Research Institute, Great Falls, MT, USA
d Department of Medicine, Columbia University, New York, NY, USA
b The

Handling Associate Editor: Domenico Pratico
Accepted 9 December 2020
Pre-press 14 January 2021

Abstract.
Background: The serine/threonine protein phosphatase, PP2A, is thought to play a central role in the molecular pathogenesis
of Alzheimer’s disease (AD), and the activity and substrate specificity of PP2A is regulated, in part, through methylation and
demethylation of its catalytic subunit. Previously, we found that transgenic overexpression of the PP2A methyltransferase,
LCMT-1, or the PP2A methylesterase, PME-1, altered the sensitivity of mice to impairments caused by acute exposure to
synthetic oligomeric amyloid-␤ (A␤).
Objective: Here we sought to test the possibility that these molecules also controlled sensitivity to impairments caused by
chronically elevated levels of A␤ produced in vivo.
Methods: To do this, we examined the effects of transgenic LCMT-1, or PME-1 overexpression on cognitive and electrophysiological impairments caused by chronic overexpression of mutant human APP in Tg2576 mice.
Results: We found that LCMT-1 overexpression prevented impairments in short-term spatial memory and synaptic plasticity
in Tg2576 mice, without altering APP expression or soluble A␤ levels. While the magnitude of the effects of PME-1
overexpression in Tg2576 mice was small and potentially confounded by the emergence of non-cognitive impairments,
Tg2576 mice that overexpressed PME-1 showed a trend toward earlier onset and/or increased severity of cognitive and
electrophysiological impairments.
Conclusion: These data suggest that the PP2A methyltransferase, LCMT-1, and the PP2A methylesterase, PME-1, may
participate in the molecular pathogenesis of AD by regulating sensitivity to the pathogenic effects of chronically elevated
levels of A␤.
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INTRODUCTION
Protein phosphatase 2A (PP2A) is a serine/
threonine phosphatase that has been implicated in the
molecular pathogenesis of Alzheimer’s disease (AD)
by multiple lines of evidence [1]. PP2A expression
and activity is reduced in AD brains [2–5], and PP2A
acts as the principal phosphatase for phosphorylated
forms of microtubule-associated binding protein, tau,
that are linked to AD [6]. In animal models, genetically reducing PP2A activity results in AD-like
pathology and cognitive deficits [7–13], while pharmacological activation of PP2A reduces AD-like
cognitive impairments and pathology [14–18]. Here
we sought to understand the role and therapeutic
potential of methylation-dependent PP2A regulation
in AD pathogenesis.
PP2A is a heterotrimeric enzyme composed of
a catalytic subunit, a structural subunit, and a regulatory subunit [19]. Multiple isoforms exist for
each of these subunits, and the combination of different subunit isoforms leads to the formation of
different heterotrimeric holoenzymes with different
expression patterns and substrate specificities [20].
PP2A activity is regulated through a complex process
involving regulated assembly and disassembly, posttranslational modifications, and interactions with
inhibitory proteins [19, 21, 22]. One of the mechanisms controlling PP2A activity involves methylation
of the C-terminal leucine of the catalytic subunit,
and in mice, methylation of PP2A is carried out by
leucine carboxyl methyltransferase 1 (LCMT-1) and
demethylation is carried out by protein phosphatase
methylesterase 1 (PME-1). PP2A catalytic subunit
methylation promotes the formation of B55␣ subunitcontaining holoenzymes that exhibit the highest tau
phosphatase activity [23, 24], and a role for reduced
PP2A methylation in AD pathogenesis is suggested
by the reduced LCMT-1 expression observed in AD
brains [25, 26]. In addition, dysregulated PP2A activity resulting from impaired PP2A methylation is
thought to be one of the molecular mechanisms
underlying the link between hyperhomocysteinemia
and increased risk for AD [27].
We found previously that LCMT-1 and PME-1
overexpression altered sensitivity to cognitive and
electrophysiological impairments caused by acute
exposure to elevated levels of amyloid-␤ (A␤) [28].
To explore further the involvement and therapeutic potential of this pathway in AD, we sought to
determine whether LCMT-1 and PME-1 overexpression might alter sensitivity to impairments caused

by chronically elevated A␤ levels in APP transgenic
mice. To do this, we tested cognitive performance and
synaptic plasticity in Tg2576 APP transgenic mice
that overexpressed either LCMT-1 or PME-1. We
found that LCMT-1 overexpression protected mice
from cognitive impairments in a 2-day radial arm
water maze task as well as impairments in long-term
potentiation (LTP) caused by transgenic expression
of mutant APP. The protective effects of LCMT-1
overexpression in Tg2576 mice were associated with
trends for reduced tau phosphorylation and restored
LCMT-1 expression that suggest possible mechanisms for these effects. Our data also suggest that
PME-1 overexpression may increase the sensitivity
of mice to impairments caused by expression of the
mutant APP transgene in Tg2576 mice. However, the
magnitude of the effects in these animals was small
and potentially confounded by the emergence of noncognitive impairments in animals that overexpressed
both PME-1 and mutant APP. Together our data support the involvement of LCMT-1 and PME-1 in the
molecular pathogenesis of AD as well as their potential as a novel targets for AD prevention or treatment.
MATERIALS AND METHODS
Animals
Subjects in this study were transgenic mice
carrying combinations of the CaMKII-tTA [29], tetOLCMT, tetO-PME [28] and Tg2576 [30] as indicated.
Single transgenic animals carrying only either a
CaMKII-tTA, tetO-LCMT, or tetO-PME transgene
were used as controls. Experimental animals were
generated from crosses of either tetO-LCMT; CaMKtTA or tetO-PME; CaMK-tTA double transgenic
mice in a C57BL6/J background to Tg2576 mice in
a 129S6 background as outlined in Fig. 1. Equivalent numbers of male and female mice were used for
all experiments and animals were tested in groups of
10–12. All procedures involving animals were conducted in strict accordance with protocols approved
by the Columbia University Institutional Animal
Care and Use Committee (USDA Registration #21R-0082; AAALAC Accreditation #000687; NYDOH
#A141).
Radial arm water maze
Testing was performed in a 120 cm diameter
pool containing a six-arm radial maze insert (San
Diego Instruments) and filled with opaque water
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Fig. 1. Diagram of the mating scheme in which LCMT-1 or PME-1 overexpressing animals were crossed to Tg2576 transgenic mice to
generate offspring in an F1 hybrid background for experiments.

as described previously [31]. Mice were tested in
15 × 1 min trials on each of 2 consecutive days. The
location of the escape platform was held constant
during testing, but the start location was pseudorandomly varied throughout. On the first day, training
alternated between visible and hidden platform trials, while on the second day only hidden platform
trials were conducted. Water temperature was maintained at approximately 24◦ C and mice were dried
and placed in a clean heated cage between trials to
prevent hypothermia. Entries into maze arms that did
not contain the escape platform were scored as errors.
Data are presented as the average number of errors
committed during blocks of 3 training trials.
Visible platform water maze
This task was conducted in a 120 cm diameter pool
(San Diego Instruments) filled with opaque water,
but without the partitions used for the radial arm
water maze task. Training for this task was carried
out over 2 days with 3 morning and 3 afternoon trials
on each day. Intertrial intervals were 15 to 20 min, and
rest periods between morning and afternoon sessions
were 2-3 h. Each trial was a maximum of 120 s during
which time the animals were required to swim to a
marked visible escape platform located just above the
water surface. Animals that did not reach the platform
within the allotted time were guided to it and allowed
to sit there for 15 s before returning to their home
cage. The location of the platform was varied among
4 different locations such that it was not present in
the same location on any two successive trials. Water
temperature was maintained at approximately 24◦ C,
and animals were dried and placed in a clean warmed
cage after each trial to prevent hypothermia. Animal

movements were recorded using a video-tracking
system (Noldus) and time required to reach the platform (latency) and swim speed were determined
using Ethovision XT behavioral analysis software
(Noldus).
Electrophysiological studies
Extracellular field potential recordings were performed on acute hippocampal slices prepared as
described previously [32] from sibling mice with the
genotypes and ages indicated in the text. Animals
were euthanized by cervical dislocation, a method
of euthanasia approved by the Panel on Euthanasia of the American Veterinary Medical Association
that yields viable anesthetic-free tissue suitable for
electrophysiological recordings. Brains were then
rapidly removed and cooled in ice cold ASCF consisting of in mM: 124 NaCl, 4.4 KCl, 1 Na2 HPO4 ,
25 NaHCO3 , 2 CaCl2 , 2 MgCl2 , and 10 glucose.
Hippocampi were then dissected and sliced into
400 M sections using a tissue chopper. Slices were
incubated at 29◦ C in an interface chamber under continuous perfusion (2 ml/min) with oxygenated ACSF
and allowed to recover for a minimum of 90 min
prior to recording responses in the CA1 region to
stimulation of Schaffer collateral projections with a
bipolar electrode (FHC Inc.). Field potential signals
were acquired using a Axoclamp-2A amplifier (Axon
Instruments) and pClamp10.6 software (Molecular
Devices). Input/output relationships were determined
prior to each recording and stimulus intensities that
elicited 30% of the maximal response were utilized.
Stable baselines were obtained for a minimum of
15 min prior to drug or vehicle application and a
theta-burst stimulation protocol consisting of 3 trains
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Table 1
shows the values obtained for transgenic human A␤ species and endogenous murine A␤ species obtained by ELISAs performed on hippocampal homogenates from 7-8-month-old animals from the indicated genotype groups expressed in pmol of A␤ per gram of total
protein ± SEM
Control (N = 8)

Genotype
APP (N = 7)

LCMT + APP (N = 7)

T-test

human A␤40
human A␤42

n. d.
n. d.

491.7 ( ± 47.82)
59.37 ( ± 4.58)

484.3 (± 45.06)
63.21 ( ± 5.95)

murine A␤40
murine A␤42

16.18 ( ± 0.276)
7.882 ( ± 0.496)

16.01 ( ± 0.634)
9.112 ( ± 0.619)

17.23 ( ± 0.688)
8.707 ( ± 0.578)

t = 0.112; p = 0.9126
t = 0.5112; p = 0.6185
ANOVA
F = 1.454; p = 0.2585
F = 1.287; p = 0.2992

(n.d., not detected)

separated by 15 s intervals with each train consisting of 10 bursts at 5 Hz and each burst consisting
of 5 pulses at 100 Hz was used to elicit LTP. Data
analysis was performed using Clampfit 10.6 software
(Molecular Devices).

for 2 h. Immunoreactive bands were detected using
an Odyssey 9120 infrared imaging system and
analyzed using Image Studio Lite v5.2.5 software
(RRID:SCR 014211) (LI-COR).
Aβ ELISA

Western blotting
Animals were euthanized by cervical dislocation,
an AVMA approved method that allows for rapid
removal of non-hypoxic brains. Hippocampi were
then rapidly dissected, snap frozen in liquid nitrogen
and stored at –80◦ C prior to homogenization for western blot analysis. Hippocampal homogenates were
prepared by sonication at 95◦ C in aqueous buffer containing 2% lithium dodecyl sulfate and 50 mM Tris
pH 7.5. Total protein concentrations were determined
by bicinchoninic acid assay according to the manufacturer’s instructions (Micro BCA protein assay
kit, Thermo Fisher) and 10–20 g of total protein
was loaded per lane on NuPage 4–12% Bis-Tris
gels (Invitrogen). Proteins were transferred to PVDF
membranes using an i-Blot gel transfer device (Invitrogen). Membranes were blocked with Seablock
(Pierce) for 1 h at room temperature, and probed with
the indicated primary antibodies (rabbit anti-APP
(1:1000) Cell Signaling #2452 RRID:AB 10694227;
mouse anti-phospho-tau clone PHF1 (1:500) Peter
Davies; mouse anti-phospho-tau clone CP13 (1:500)
Peter Davies; rabbit anti-tau clone EP2456Y (1:8000)
Abcam #Ab76128 RRID:AB 1524475; rabbit antiPME (1:1000) Millipore #07-095 RRID:AB 310373;
mouse anti-LCMT-1 clone 4A4 (1:1000) Cell Signaling #5691 RRID:AB 10949100; mouse anti-␤-actin
(1:40,000) Licor #926-42212; rabbit anti-␤-actin
(1:40,000) Licor #926-42210 RRID:AB 1850027)
overnight at 4◦ C, then washed and incubated with
infrared dye-labeled Goat anti-rabbit (IRDye 800CW,
LI-COR) and Goat anti-mouse (IRDye 680RD, LICOR) secondary antibodies at room temperature

Levels of soluble A␤1–40 and A␤1–42 were
measured in diethylamine extracted hippocampal
homogenates using commercially available human
A␤40 or A␤42 ELISA kits (Invitrogen) or murine
A␤40 or A␤42 ELISA kits (FUJIFILM Wako Pure
Chemical Corporation) as described previously [33].
Chromogenic signals generated in these assays were
quantified by measuring absorbance at 450 nm using
an Infinite M200 plate reader (Tecan).
Statistical analysis
Tests for statistical significance between groups
were performed using Prism 8 (Graphpad Software, San Diego, CA, USA). 2-way ANOVA
comparisons—with or without repeated measures
as dictated by the experimental design—were used
for analysis of all experiments involving multiple
groups with the exception of data shown in Table 1
where comparisons between the control, APP, and
APP + LCMT groups was performed using one-way
ANOVA. Student’s unpaired, two-tailed t-tests were
used for comparisons of data in Table 1 involving
two groups. Dunnett’s post-hoc comparisons to controls were performed to test for significant differences
among groups in experiments with repeated measures, and Sidak’s post-hoc tests were performed on
data from experiments without repeated measures.
Tukeys’ comparisons were used to test for significant
differences among any of the groups for the data presented in Fig. 2C. The results of these tests together
with their associated p values are presented in the
legends for their corresponding figure.
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Fig. 2. LCMT overexpression protects against cognitive impairments in Tg2576 mice. A) Plot of average number of errors committed
( ± SEM) during each 3-trial training block of a 2-day radial arm water maze task for 6-7-month-old mice that carried the Tg2576 APP
transgene in combination with transgenic LCMT overexpression (LCMT + APP), or 6-7-month-old animals that carried the Tg2576 APP
transgene alone (APP), overexpressed LCMT alone (LCMT), or controls. 2-way RM ANOVA for errors on day 2 (blocks 6–10) with
group and block as factors shows a significant effect of group (F(3,76) = 9.456, p < 0.0001). Dunnett’s multiple comparisons show that
the APP group was significantly different from each of the other three groups (p = 0.0025 for LCMT + APP, p = 0.0003 for LCMT, and
p < 0.0001 for control). B) Plot of the average escape latency ( ± SEM) for 6-7-month-old animals from the indicated groups during training
on a visible platform water maze task showed no significant differences between groups (2-way RM ANOVA for effect of group with
group and block as factors F(3, 76) = 2.202, p = 0.0947). C) Plot of the average swim speed ( ± SEM) for the indicated groups during
training on the visible platform water maze task described in B showed a significant difference between groups overall (2-way RM ANOVA
for effect of group with group and block as factors F(3, 76) = 2.948, p = 0.0381), but no significant differences in pairwise comparisons
(Tukey’s comparisons p > 0.05 for all). D) Plot of average number of errors committed ( ± SEM) during each 3-trial training block of a
2-day radial arm water maze task for 9-10-month-old mice that carried the Tg2576 APP transgene in combination with transgenic LCMT
overexpression (LCMT + APP), or 9-10-month-old animals that carried the Tg2576 APP transgene alone (APP), overexpressed LCMT
alone (LCMT), or controls. 2-way RM ANOVA for errors on day 2 (blocks 6–10) with group and block as factors shows a significant
effect of group (F(3, 65) = 6.135, p = 0.0010). Dunnett’s multiple comparisons show that the APP group was significantly different from
each of the other three groups (p = 0.0220 for LCMT + APP, p = 0.0006 for LCMT and p = 0.0029 for control). E) Plot of the average
escape latency ( ± SEM) for 9-10-month-old animals from the indicated groups during training on a visible platform water maze task
reveals no significant differences between groups (2-way RM ANOVA for latency with group and block as factors shows no significant
effect of group F(3, 64) = 0.961, p = 0.4167). F) Plot of the average swim speed ( ± SEM) for the indicated groups during training on the
visible platform water maze task described in B reveals no significant differences between groups (2-way RM ANOVA for speed with
group and block as factors shows no significant effect of group F(3, 64) = 0.5046, p = 0.6805). For experiments on 6-7-month-old animals:
N = 27 control, 22 APP, 16 LCMT, 15 LCMT + APP. For experiments on 9-10-month-old animals: N = 17 control, 17 APP, 19 LCMT,
16 LCMT + APP.

RESULTS
Transgenic LCMT-1 overexpression protects
against cognitive and electrophysiological
impairments in Tg2576 mice
To assess the effects of increased LCMT-1
expression on cognitive impairments resulting from
chronically elevated levels of A␤, we utilized the
Tg2576 line of APP transgenic mice [30]. The

Tg2576 transgene encodes a 695 amino acid form of
human APP carrying the Swedish (K670N, M671L)
mutation under the control of the hamster prion protein promoter, and animals that carry this transgene
exhibit well-characterized behavioral and electrophysiological impairments [34, 35]. We crossed these
animals to mice carrying both the CaMKII-tTA
and tetO-LCMT transgenes, which together result
in increased expression of murine LCMT-1 in the
murine forebrain [28]. We then assessed the cognitive
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performance of the resulting offspring on a 2-day
radial arm water maze task at 6-7 months of age, an
early stage in the development of neurodegenerative
phenotypes in Tg2576 mice [30, 34, 36, 37], to determine whether LCMT overexpression might prevent
or delay the onset of cognitive impairments in these
animals. We found that animals that carried the APP
transgene alone committed significantly more errors
in this task when compared to controls at this age,
whereas APP transgenic animals that also expressed
the LCMT-1 transgene (LCMT + APP) were indistinguishable in their performance from the control group
(Fig. 2A).
We also compared the performance of these same
animals on a visible platform water maze task that
relies only on an association between a visual cue
and the escape platform, rather than spatial memory performance. The performance of all groups in
the visible platform water maze task was similar,
both with respect to their latency to reach the escape
platform, and with respect to their swimming speed
(Fig. 2B, C). The absence of impairments in this nonspatial visible platform water maze task suggests that
the performance differences we observe in the 2-day
radial arm water maze among these groups do not
result from non-cognitive differences in visual perception, motivation or swimming ability. Together
these data suggest the existence of a cognitive impairment in short-term spatial memory in Tg2576 mice
that can be prevented through transgenic overexpression of LCMT-1.
As a further test of the ability of LCMT-1 overexpression to protect against cognitive impairments
in Tg2576 mice, we performed the same behavioral
tests on a separate group of 9-10-month-old animals,
an age when cognitive impairments are reported to
be well-established in Tg2576 animals [34]. Again,
mice that carried the APP transgene alone committed
significantly more errors in this task when compared
to controls at this age, whereas the performance APP
transgenic animals that also expressed the LCMT-1
transgene (LCMT + APP) was indistinguishable from
the control group (Fig. 2D). As was the case at 6-7
months of age, we found that all groups performed
similarly in the visible platform water maze task
at 9-10 months, further supporting the conclusion
that transgenic overexpression of LCMT-1 protects
against cognitive impairments in short-term spatial
memory in Tg2576 mice (Fig. 2E, F).
Synaptic plasticity in the hippocampus is thought
to be required for normal spatial memory, and impairments in synaptic plasticity have been identified in

Tg2576 mice that are thought to contribute to the cognitive impairments exhibited by these animals [36,
37]. To determine whether transgenic LCMT-1 overexpression might also protect against impairments in
synaptic plasticity in APP Tg2576 transgenic mice,
we compared the magnitude of long-term potentiation (LTP) among APP and LCMT-1 transgenic and
control groups at both 7-8 and 10-11 months of age.
Acute hippocampal slices were prepared from these
animals, and LTP was induced at Schaffer collateral
synapses by theta-burst stimulation. Consistent with
previous reports [36, 37], we found that the magnitude of LTP in slices from animals that carried the
APP transgene alone was significantly decreased relative to controls at both of these ages (Fig. 3A, B).
In contrast, the magnitude of LTP in slices prepared
from animals expressing both the mutant APP and
LCMT-1 transgenes (LCMT + APP) was similar to
the control group. These data suggest that, in addition
to protecting against cognitive impairments, LCMT-1
overexpression also protects against impairments in
synaptic plasticity that result from transgenic expression of mutant APP.
One way in which transgenic LCMT-1 overexpression could protect against cognitive and
electrophysiological impairments in Tg2576 mice is
by reducing transgenic APP expression or A␤ production in these animals. To test this possibility, we
performed western blots for APP on hippocampal
homogenates prepared from these groups at 7-8 or
10-11 months of age. As shown in Fig. 4A and
B, and consistent with published reports [30, 38],
we found that mice carrying the Tg2576 transgene
expressed APP at 4-5 x endogenous levels. However,
neither transgenic nor endogenous APP protein levels were significantly affected by transgenic LCMT-1
overexpression. To test the possibility that transgenic LCMT-1 overexpression acted by altering
A␤ production in Tg2576 mice, we performed
enzyme-linked immunosorbent assays (ELISAs) for
human and murine A␤40 and A␤42 in hippocampal homogenates prepared from 7-8-month-old mice
that expressed the Tg2576 transgene alone or in
combination with transgenic LCMT-1 overexpression (Table 1). The results of this analysis revealed
no significant differences between groups for either
the transgenic human or endogenous murine A␤40 or
A␤42 species. Together, and consistent with our previous data on the effect of LCMT-1 overexpression
on endogenous A␤ levels [28], these data suggest that
transgenic LCMT-1 overexpression does not protect
against cognitive and electrophysiological impair-
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Fig. 3. LCMT overexpression protects against electrophysiological impairments in Tg2576 mice. A) Time course of averaged Schaffer
collateral fEPSP responses ( ± SEM) prior to and following delivery of theta-burst stimulation (arrow) in hippocampal slices prepared
from 7-8-month-old mice that carried the Tg2576 APP transgene in combination with transgenic LCMT overexpression (LCMT + APP), or
7-8-month-old animals that carried the Tg2576 APP transgene alone (APP), overexpressed LCMT alone (LCMT), or controls. 2-way RM
ANOVA for fEPSP responses over the last 20 min of recording with group and time as factors shows a significant effect of group (horizontal
bar; F(3, 60) = 5.297, p = 0.0026). Dunnett’s multiple comparisons show that the APP group was significantly different from each of the
other three groups (p = 0.0481 for LCMT + APP, p = 0.0033 for LCMT and p = 0.0019 for control). N = 14 control, 13 APP, 18 LCMT, 19
LCMT + APP. Representative traces of field potential responses prior to TBS, and during the last 20 min of recording are shown above for
each of the indicated genotypes. B) Time course of averaged Schaffer collateral fEPSP responses ( ± SEM) prior to and following delivery
of theta-burst stimulation (arrow) in hippocampal slices prepared from 10-11-month-old mice that carried the Tg2576 APP transgene in
combination with transgenic LCMT overexpression (LCMT + APP), or 10-11-month-old animals that carried the Tg2576 APP transgene
alone (APP), overexpressed LCMT alone (LCMT), or controls. 2-way RM ANOVA for fEPSP responses over the last 20 min of recording with
group and time as factors shows a significant effect of group (horizontal bar; F(3, 43) = 7.328, p = 0.0004). Dunnett’s multiple comparisons
show that the APP group was significantly different from each of the other three groups (p = 0.0003 for LCMT + APP, p = 0.0183 for LCMT
and p = 0.0013 for control). N = 11 control, 12 APP, 12 LCMT, 12 LCMT + APP. Representative traces of field potential responses prior to
TBS, and during the last 20 min of recording are shown above for each of the indicated genotypes.

ments in Tg2576 mice by reducing APP expression
or A␤ production.
A␤ has been suggested to exert its pathogenic
effects, at least in part, through the microtubule binding protein, tau, and consistent with this model,
genetically eliminating tau has been found to protect
against impairments in APP transgenic mice [39, 40].
Elevated levels of A␤ have also been found to increase
tau phosphorylation at sites linked to human neurodegeneration [41–46]. Since protein phosphatase
2A plays a central role in regulating tau phosphorylation [1], one way LCMT-1 overexpression might
exert its protective effects is by increasing PP2Amediated tau phosphatase activity, thereby reducing
pathogenic, A␤-induced increases in tau phosphorylation. To explore this possibility, we performed
western blots for two AD-related phospho-tau epitopes that were shown previously to respond to both

PP2A activity and A␤ levels [10, 28, 41, 43–45,
47–49]. Our analysis revealed no significant differences in tau phosphorylation among any of the groups
tested at either 7-8 or 10-11 months of age for either
the serine 396/404 or serine 202 phospho-tau epitopes (Fig. 4A, B). However, we did observe a trend
for increased tau phosphorylation at these sites in
APP transgenic animals that was absent in animals
expressing both the APP and LCMT-1 transgenes,
raising the possibility that increased tau dephosphorylation downstream of LCMT-1 may contribute to
its protective effects.
LCMT-1 levels have been reported to be reduced
in AD brains, suggesting that reduced LCMT-1 activity may contribute to the molecular pathogenesis
of AD [25, 26]. To further explore the relationship
between LCMT-1 expression and AD-related pathology, we compared the levels of LCMT-1 expression in
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Fig. 4. (Continued).
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Fig. 4. The effect of LCMT overexpression on APP expression, tau phosphorylation, and LCMT protein levels in Tg2576 mice. A, B)
Representative western blots showing anti-APP, phospho-tau serine 396/404 and serine 202, total tau, and LCMT immunoreactivity in
hippocampal homogenates prepared from 7-8 (A) or 9-10-month-old (B) control, LCMT overexpressing, Tg2576 APP transgenic, or LCMT
overexpressing/APP transgenic mice together with corresponding histograms showing average normalized immunoreactivity ( ± SEM) in
each group. APP genotype significantly affected APP expression (2-way ANOVA with APP and LCMT genotype as factors: F(1, 20) = 169.7,
p < 0.0001 for 7-8-month-old mice and F(1, 20) = 1157, p < 0.0001 for 10-11-month-old mice). Sidak’s multiple comparisons showed no
significant differences in APP expression between control and LCMT groups (p = 0.9873 for 7-8-month-old mice and p = 0.9804 for 1011-month-old mice) or between APP and LCMT + APP groups (p = 0.9815 for 7-8-month-old and, p = 0.9843 for 10-11-month-old mice).
Animals carrying an APP transgene alone showed a trend for increased tau phosphorylation at serine residues 396/404 (APP:107.3 ± 10.46%
versus control: 100 ± 11.53, LCMT: 98.3 ± 10.01, APP:107.3 ± 10.46, LCMT + APP: 97.5 ± 14.22 at 7-8 months, and APP:118.0 ± 9.92%
versus control: 100 ± 5.15, LCMT: 107.2 ± 7.28, LCMT + APP: 107.5 ± 8.99 at 10-11 months) that was not statistically significant (2-way
ANOVA test for interaction with APP and LCMT genotype as factors: F(1,20) = 0.174, p = 0.6811 for 7-8-month-old mice and F(1,20) = 1.212,
p = 0.2840 for 10-11-month-old mice). Animals carrying an APP transgene alone showed a similar trend for increased tau phosphorylation
at serine residue 202 (APP:106.9 ± 9.37% versus control: 100 ± 11.68, LCMT: 100.5 ± 7.64, LCMT + APP: 97.0 ± 9.36 at 7-8 months,
and APP:114.0 ± 18.47% versus control: 100 ± 13.92, LCMT: 97.0 ± 9.701, LCMT + APP: 102.6 ± 16.65 at 10-11 months) that was not
statistically significant (2-way ANOVA test for interaction with APP and LCMT genotype as factors: F(1,20) = 0.2877, p = 0.5976 for 7-8month-old mice and F(1,20) = 0.07876, p = 0.7819 for 10-11-month-old mice). Neither LCMT overexpression nor APP transgene expression
significantly affected endogenous tau levels (2-way ANOVA for effect of LCMT transgene with APP and LCMT genotype as factors:
F(1,44) = 0.0111, p = 0.9166 for 7-8-month-old mice, and F(1,44) = 0.06945, p = 0.7934 for 10-11-month-old mice);(2-way ANOVA for
effect of APP transgene with APP and LCMT genotype as factors: F(1,44) = 0.0223, p = 0.8819 for 7-8-month-old mice and F(1,44) = 4.196,
p = 0.0465 for 10-11-month-old mice). As expected, transgenic LCMT expression significantly affected LCMT protein levels (2-way ANOVA
with LCMT and APP genotype as factors: F(1,20) = 14.1, p = 0.0012 for 7-8-month-old mice and F(1,20) = 46.97, p < 0.0001 for 10-11-monthold mice. In addition, for 10-11-month-old mice, Sidak’s multiple comparisons show a significant decrease in total LCMT expression in
the APP transgenic group relative to controls (p = 0.0204), and in the LCMT + APP group relative to LCMT alone group (p = 0.0134).
Transgenic LCMT overexpression did not significantly affect the amount of PP2A catalytic subunit that was demethylated at Leucine 309
(2-way ANOVA with LCMT and APP genotype as factors: F(1,20) = 0.5316, p = 0.4744 and F(1,20) = 0.3604, p = 0.5550 respectively for
7-8-month-old mice, and F(1,20) = 0.7365, p = 0.4010 and F(1,20) = 0.0877, p = 0.7702 respectively for 10-11-month-old mice). Transgenic
LCMT overexpression also did not significantly affect the total amount of PP2A catalytic subunit (2-way ANOVA with LCMT and APP
genotype as factors: F(1,20) = 0.4440, p = 0.5128 and F(1,20) = 0.1909, p = 0.6669 respectively for 7-8-month-old mice, and F(1,20) = 0.1213,
p = 0.7313 and F(1,20) = 0.2888, p = 0.5969 respectively for 10-11-month-old mice). For all blots band intensities in each lane were normalized
to corresponding actin or total tau immunoreactivity in that lane and values were expressed as a percentage of the mean of the control group
(N = 6 per group).

hippocampal homogenates prepared from controls
and mice that expressed the APP and LCMT-1 transgenes alone or together. Consistent with a potential
role for reduced LCMT-1 expression in AD pathogenesis, we found a significant reduction in LCMT-1
protein levels in 10-11-month-old APP transgenic
mice that was compensated for by transgenic LCMT1 overexpression (Fig. 4A, B). If reduced LCMT-1
protein levels contribute to the cognitive and electrophysiological impairments in Tg2576 animals, then
compensation for this decrease could underlie the
protective effects of transgenic LCMT-1 overexpression that we observe. Moreover, if the APP-related
decrease in LCMT-1 levels also contributes to the
trend for increased tau phosphorylation in these animals, then transgenic LCMT-1 overexpression may
similarly counteract this effect. However, we were
unable to detect a significant effect of LCMT overexpression on demethyl-PP2A levels in either control or
APP transgenic animals, suggesting that either subtle
changes in the levels of PP2A methylation underlie
the effects of LCMT overexpression, or LCMT acts
via mechanisms other than increased PP2A methylation to protect mice from impairments caused by
Tg2576 expression (Fig 4A, B).

Transgenic PME-1 overexpression produces a
trend for increased behavioral and
electrophysiological impairments in Tg2576 mice
PP2A methylation by LCMT-1 is reversed by the
demethylating activity of PME-1 [50, 51]. Consistent
with the opposing actions of these enzymes, we found
previously that transgenic overexpression of LCMT-1
and PME-1 also exerted opposite effects on sensitivity to impairments caused by acute exposure to
exogenously applied A␤ [28]. To test whether PME1 overexpression might also increase the sensitivity of
mice to impairments caused by chronically elevated
levels of A␤, we generated animals that expressed
the PME-1 and Tg2576 transgenes (PME + APP), the
Tg2576 (APP) or PME-1 (PME) transgenes alone,
and non-expressing controls. To determine whether
PME-1 overexpression might advance the onset of
cognitive impairments in A␤PP transgenic mice, we
compared their performance in a 2-day radial arm
water maze task at 3-4 months of age, when cognitive
impairments are not yet apparent in Tg2576 animals.
We found that there was a clear trend for increased
errors in the group that expressed both the APP and
PME transgenes. However, the difference between
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Fig. 5. The effect of PME overexpression on cognitive impairments in Tg2576 mice. A) Plot of average number of errors committed (±SEM)
during each 3-trial training block of a 2-day radial arm water maze task for 3-4-month-old mice that carried the Tg2576 APP transgene in
combination with transgenic PME overexpression (PME + APP), carried the Tg2576 APP transgene alone (APP), overexpressed PME alone
(PME), or controls. The PME + APP showed a trend for increased errors compared to all other groups that was not statistically significant
(2-way RM ANOVA for errors on day 2 (blocks 6–10) with group and block as factors, F(3,51) = 1.783, p = 0.1621 for group). N = 12
control, 12 APP, 16 PME, 15 PME + APP. B) Plot of the average escape latency (±SEM) for 3-4-month-old animals from the indicated
groups during training on a visible platform water maze task reveals significant differences between groups (2-way RM ANOVA for latency
with group and block as factors shows no significant effect of group F(3,50) = 7.865, p = 0.0002). Dunnett’s multiple comparisons show
that the PME + APP group was significantly different from each of the other three groups (p = 0.0002 for control, p = 0.0018 for APP, and
p = 0.0026 for PME). N = 13 control, 10 APP, 16 PME, 15 PME + APP. C) Plot of the average swim speed (±SEM) for the indicated groups
during training on the visible platform water maze task described in B reveals no significant differences between groups (2-way RM ANOVA
for speed with group and block as factors shows no significant effect of group F(3,50) = 0.6083, p = 0.6127). D) Plot of average number of
errors committed (±SEM) during each 3-trial training block of a 2-day radial arm water maze task for 6-7-month-old mice that carried the
Tg2576 APP transgene in combination with transgenic PME overexpression (PME + APP), carried the Tg2576 APP transgene alone (APP),
overexpressed PME alone (PME), or controls. 2-way RM ANOVA for errors on day 2 (blocks 6–10) with group and block as factors shows a
significant effect of group (F(3,72) = 15.46, p < 0.0001). Dunnett’s multiple comparisons show that the both the PME + APP and APP groups
were significantly different from both control and PME alone groups (p < 0.001 for all comparisons) but were not significantly different
from one another (p = 0.2956). E) Plot of the average escape latency (±SEM) for 6-7-month-old animals from the indicated groups during
training on a visible platform water maze task reveals significant differences between groups (2-way RM ANOVA for effect of group with
group and block as factors F(3,72) = 4.954, p = 0.0035). Dunnett’s multiple comparisons show that the PME + APP group was significantly
different from the control (p = 0.0012) and PME (p = 0.0167) groups, but not the APP group (p = 0.1064). F) Plot of the average swim speed
(±SEM) for the indicated groups during training on the visible platform water maze task described in B reveals significant differences
between groups (2-way RM ANOVA for effect of group with group and block as factors F(3,72) = 12.15, p < 0.0001). Dunnett’s multiple
comparisons show that the PME + APP group was significantly different from each of the other groups (p < 0.0001 for control, p = 0.0034
for PME alone, p = 0.0005 for APP alone). For experiments on 6-7-month-old animals: N = 27 control, 22 APP, 13 PME, 14 PME + APP.

this group and the others did not reach statistical
significance (Fig. 5A). In addition, the PME + APP
group also exhibited a significant increase in escape
latency in the initial training blocks of a visible
platform water maze task (Fig. 5B). Since this task
requires only a simple association between the visible
platform and escape, their impaired performance in
this task suggests that the combination of mutant APP
and PME-1 overexpression adversely affects a noncognitive aspect behavior required for normal water

maze performance that may also adversely impact
performance the performance of this group in the
2-day radial arm water maze task.
To test whether PME-1 overexpression may
increase the severity of cognitive impairments in
mutant APP transgenic mice, we performed these
same behavioral tests on a separate group of animals
at 6-7 months of age. Here, we found that animals
that expressed APP alone, or in combination with
the PME-1 transgene were comparably impaired in
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Fig. 6. The effect of PME overexpression on LTP impairments in Tg2576 mice. A) Time course of averaged Schaffer collateral fEPSP
responses (±SEM) prior to and following delivery of theta-burst stimulation (arrow) in hippocampal slices prepared from 4-5-month-old
mice that carried the Tg2576 APP transgene in combination with transgenic PME overexpression (PME + APP), or 4-5-month-old animals
that carried the Tg2576 APP transgene alone (APP), overexpressed PME alone (PME), or controls. 2-way RM ANOVA for fEPSP responses
over the last 20 min of recording with group and time as factors shows a significant effect of group (horizontal bar; F(3,65) = 4.717,
p = 0.0049), however, the trend for increased impairment in the PME + APP group relative to the APP alone group was not statistically
significant (Dunnett’s multiple comparisons p = 0.1165). N = 17 control, 13 APP, 24 PME, 15 PME + APP. Representative traces of field
potential responses prior to TBS, and during the last 20 min of recording are shown above for each of the indicated genotypes. B) Time course
of averaged Schaffer collateral fEPSP responses ( ± SEM) prior to and following delivery of theta-burst stimulation (arrow) in hippocampal
slices prepared from 7-8-month-old mice that carried the Tg2576 APP transgene in combination with transgenic PME overexpression
(PME + APP), or 7-8-month-old animals that carried the Tg2576 APP transgene alone (APP), overexpressed PME alone (PME), or controls.
2-way RM ANOVA for fEPSP responses over the last 20 min of recording with group and time as factors shows a significant effect of
group (horizontal bar; F(3,45) = 15.17, p < 0.0001); however, the trend for increased impairment in the PME + APP group relative to the APP
alone group was not statistically significant (Dunnett’s multiple comparisons p = 0.2791). N = 11 control, 8 APP, 14 PME, 16 PME + APP.
Representative traces of field potential responses prior to TBS, and during the last 20 min of recording are shown above for each of the
indicated genotypes.

their performance on a 2-day radial arm water maze
task (Fig. 5D). As was the case for these animals at
3-4 months, we found that the APP + PME-1 group
showed a significant reduction in escape latency on a
visible platform water maze task at this age (Fig. 5E).
These animals also showed a significant reduction
in swimming speed at that was not evident at 3-4
months, and together this reduced swim speed, and
the increased escape latency of this group further support the conclusion that the combination of mutant
APP expression and PME-1 overexpression impairs
non-cognitive aspects of behavior required for normal
water maze performance (Fig. 5F).
To determine whether transgenic PME-1 overexpression might advance the onset or increase the
severity of synaptic plasticity impairments in Tg2576
mice, we compared the magnitude of LTP among
groups of mice that expressed both the APP and PME1 transgenes, the APP transgene alone, the PME-1

transgene alone, or neither transgene. We found that
at both 4-5 months and 7-8 months of age, mice
that co-expressed the APP and PME-1 transgenes
exhibited a clear trend for reduced LTP relative to
animals that carried the APP transgene alone, and
the fact that the apparent magnitude of the difference
between these two groups was greater at 4-5 months
compared to 7-8 months is consistent with PME-1
overexpression promoting an earlier onset of LTP
impairments in APP transgenic animals (Fig. 6A, B).
However, in neither case did the difference between
these groups reach statistical significance in post-hoc
pairwise comparisons.
To explore the effects of PME-1 overexpression
on the molecular pathogenesis of cognitive and
electrophysiological impairments in Tg2576 mice,
we performed a series of western blots analogous
to those described above for LCMT-1. Hippocampal homogenates were prepared from 4-5- and
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7-8-month-old mice that expressed both the APP
and PME-1 transgenes, the APP transgene alone,
the PME-1 transgene alone, or neither transgene.
PME-1 transgene expression resulted in a 14–25-fold
increase in PME-1 immunoreactivity over endogenous levels with a high degree of inter-individual
variability (minimum of 2.3-fold/maximum of 58fold) that was not significantly affected by expression
of the mutant APP transgene (Fig. 7A, B). In addition
to increased PME-1 expression, animals expressing
the PME-1 transgene exhibited significant increases
in the amount of demethylated (L309) PP2A catalytic
subunit, as well as a small but significant increase
in the total amount of PP2A catalytic subunit in the
PME alone group relative to controls, but not the
PME + APP group relative APP alone (Fig. 7A, B).
A comparison of APP immunoreactivity in these
homogenates showed the same 4-5-fold increase in
APP protein levels in animals that carried the mutant
APP transgene that we observed in Fig. 4, with no

significant effect of transgenic PME-1 expression on
either transgenic or endogenous APP levels (Fig. 7A,
B). Western blots on these homogenates for total
and phosphorylated forms of tau showed a trend for
increased tau phosphorylation at the serine 202 and
396/404 residues in APP transgenic mice that was
similar to what we observed in Fig. 4 (Fig. 7A, B).
However, unlike the mutant APP + LMCT-1 transgene expressing animals, this trend was also apparent
in the mutant APP + PME-1 transgene expressing animals. This apparent difference between the effects
of LCMT-1 and PME-1 overexpression on APPrelated increases in tau phosphorylation is consistent
with their opposing actions on PP2A-dependent tau
dephosphorylation as well as the possibility that
changes in PP2A-dependent tau dephosphorylation
may contribute to their effects on A␤ sensitivity.
However, the magnitude of these apparent changes in
tau phosphorylation in both the PME-1 and LCMT-1
overexpressing mice, and the absence of significant

Fig. 7. The effect of PME overexpression on APP expression, tau phosphorylation and PME protein levels in Tg2576 mice. A, B) Representative western blots showing anti-APP, phospho-tau serine 396/404 and serine 202, total tau, PME, demethylated PP2A/C and total PP2A/C
immunoreactivity in hippocampal homogenates prepared from 4-5 (A) or 7-8-month-old (B) control, PME overexpressing, Tg2576 APP
transgenic, or PME overexpressing/APP transgenic mice together with corresponding histograms showing average normalized immunoreactivity (±SEM) in each group. APP genotype significantly affected APP expression (2-way ANOVA with APP and PME genotype as factors:
F(1,20) = 564.7, p < 0.0001 for 4-5-month-old mice and F(1,20) = 251.3, p < 0.0001 for 7-8-month-old mice). Sidak’s multiple comparisons
showed no significant differences in APP expression between control and PME groups (p = 0.9504 for 4-5 and p = 0.9542 for 7-8-month-old
mice) or between APP and PME + APP groups (p = 0.5961 for 4-5-month-old and, p = 0.9313 for 7-8-month-old mice). Animals carrying an
APP transgene showed a trend for increased tau phosphorylation at serine residues 396/404 (APP:113.3 ± 3.82, PME + APP: 111.3 ± 6.05
versus control: 100 ± 8.58, PME: 102.1 ± 4.08 at 4-5 months, and APP:119.5 ± 8.42, PME + APP: 115.9 ± 7.41 versus control: 100 ± 4.98,
PME: 99.0 ± 14.06 at 7-8 months) that did not reach statistical significance (2-way ANOVA with APP and PME genotype as factors:
F(1,20) = 3.725, p = 0.0679 for 4-5-month-old mice and F(1,20) = 3.806, p = 0.0652 for 7-8-month-old mice), and was not affected by PME
overexpression (Sidak’s multiple comparisons between APP and PME + APP groups: p = 0.9499 for 4-5-month-old and, p = 0.9554 for
7-8-month-old mice). Similarly, animals carrying an APP transgene showed a trend for increased tau phosphorylation at serine residue
202 (APP:108.9 ± 4.78, PME + APP: 117.9 ± 8.82 versus control: 100 ± 6.13, PME: 101.6 ± 6.87 at 4-5 months, and APP: 128.7 ± 11.25,
PME + APP: 124.3 ± 16.02 versus control: 100 ± 11.51, PME: 105.2 ± 10.04), that did not reach statistical significance (2-way ANOVA
with APP and PME genotype as factors: F(1,20) = 3.423, p = 0.0791 for 4-5-month-old mice and F(1,20) = 3.721, p = 0.0680 for 7-8-monthold mice), and was not affected by PME overexpression (Sidak’s multiple comparisons between APP and PME + APP groups (p = 0.5895
for 4-5-month-old and, p = 0.9750 for 7-8-month-old mice). Neither PME nor APP transgenes significantly affected endogenous tau levels
(2-way ANOVA for effect of PME transgene with APP and PME genotype as factors: F(1,44) = 1.098, p = 0.3005 for 4-5-month-old mice
and F(1,44) = 0.6706, p = 0.4173 for 7-8-month-old mice; 2-way ANOVA for effect of APP transgene with APP and PME genotype as
factors: F(1,44) = 0.6987, p = 0.4077 for 4-5-month-old mice and F(1,44)<0.0001, p = 0.9985 for 7-8-month-old mice). Total PME expression (endogenous + transgenic) showed a significant effect of PME genotype (2-way ANOVA with PME and APP genotype as factors:
F(1,20) = 20.39, p = 0.0002 for 4-5-month-old mice and F(1,20) = 7.611, p = 0.0121 for 7-8-month-old mice). Sidak’s multiple comparisons
showed no significant differences in PME expression between control and APP groups (p > 0.9999 for 4-5 and 7-8-month-old mice) or
between PME and PME + APP groups (p = 0.6028 for 4-5-month-old and, p = 0.5471 for 7-8-month-old mice). Transgenic PME overexpression significantly increased the amount of PP2A catalytic subunit that was demethylated at Leucine 309 (2-way ANOVA with PME and APP
genotype as factors: F(1,20) = 59.54, p < 0.0001 for 4-5-month-old mice and F(1,20) = 24.55, p < 0.0001 for 7-8-month-old mice). Sidak’s
multiple comparisons showed significant differences in demethyl-PP2A/C immunoreactivity between control and PME groups (p < 0.0001
for 4-5 and p = 0.0017 for 7-8-month-old mice) or between APP and PME + APP groups (p = 0.0003 for 4-5-month-old and, p = 0.0119 for
7-8-month-old mice). Transgenic PME overexpression also led to a small but significant increase in the total amount of PP2A catalytic
subunit in the PME relative to control group but not the PME + APP relative to APP alone group (2-way ANOVA for effect of PME with
PME and APP genotype as factors: F(1,20) = 6.077, p = 0.0229 for 4-5-month-old mice and F(1,20) = 10.73, p = 0.0048 for 7-8-month-old
mice). Sidak’s multiple comparisons showed significant differences in total PP2A/C immunoreactivity between control and PME groups
(p = 0.0230 for 4-5 and p = 0.0313 for 7-8-month-old mice) but not APP and PME + APP groups (p = 0.7376 for 4-5-month-old and p = 0.1374
for 7-8-month-old mice). For all blots band intensities in each lane were normalized to corresponding actin or total tau immunoreactivity in
that lane, and values were expressed as a percentage of the mean of the control group (N = 6 per group).
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Fig. 7. (Continued).
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changes in PP2A methylation in the LCMT-1 overexpressing mice suggest that alternate or additional,
tau or PP2A-independent mechanisms may underlie or contribute to the effects LCMT-1 and PME-1
overexpression on A␤ sensitivity (see Discussion).

DISCUSSION
Here, we sought to determine whether increased
LCMT-1 activity would protect against cognitive
impairments caused by chronically elevated A␤ levels. To do this, we utilized the Tg2576 line of
transgenic mice maintained in a congenic 129S6
background that are reported to be free of visual
impairments caused by the rd1 mutation and to
exhibit more consistent behavioral performance than
animals maintained in the original mixed B6;SJL
background [52, 53]. We crossed these animals to a
previously described line of LCMT-1 overexpressing
transgenic mice maintained in a C57BL6/J background to generate animals in a defined mixed F1
genetic background [28]. Tg2576 transgene expression in the progeny of these crosses resulted in
significantly elevated levels of both A␤40 and A␤42
(Table 1), as well as characteristic age-dependent
cognitive and electrophysiological impairments
[34, 35].
We found that transgenic LCMT-1 overexpression
protected against cognitive and electrophysiological
impairments in animals that carried the Tg2576 transgene. Moreover, these protective affects were evident
at both 6-7 and 9-10 months of age and were without effect on either endogenously or transgenically
produced APP, A␤40 , or A␤42 . These results are
consistent with our previous observations of the protective effects of transgenic LCMT-1 overexpression
on cognitive and electrophysiological impairments
caused by acutely elevated A␤ levels [28], and with
the hypothesis that LCMT-1 overexpression blocks
the pathological response to these proteins, rather
than their production. Since Tg2576 transgenic mice
produce increased levels of full-length APP, these
data also suggest that LCMT-1 overexpression may
protect against the pathological actions of other APP
proteolytic products, in addition to A␤40 and A␤42 .
PME-1 opposes the activity of LCMT-1 by
demethylating PP2A [50, 51, 54], and we found
previously that PME-1 overexpression increased sensitivity to impairments caused by acutely elevated A␤
levels [28]. We therefore sought to determine whether
increased PME-1 activity would also increase the

severity or advance the onset of cognitive or electrophysiological impairments in Tg2576 animals.
While the results of these experiments were consistent with PME overexpression leading to an earlier
onset and/or increased severity of these impairments,
the magnitude of these effects were small and potentially confounded by the emergence of non-cognitive
impairments in PME overexpressing Tg2576 animals.
One of the ways in which LCMT-1 overexpression could impact pathogenic responses to A␤, is
through increased tau dephosphorylation. Increased
LCMT-1 expression could lead to an increase in PP2A
methylation and PP2A-mediated tau dephosphorylation that antagonizes pathogenic increases in tau
phosphorylation caused by A␤ exposure. Our data
revealed trends for changes in tau phosphorylation
that were consistent with this model, as well as a possible role for restored LCMT-1 expression in LCMT-1
overexpressing Tg2576 mice that parallels a proposed
role for the decreased LCMT-1 expression observed
in AD brains.
However, the modest changes in tau phosphorylation that we observed in these animals suggest
that additional, or alternate downstream targets may
account for, or contribute to the protective effects of
LCMT-1 overexpression. PP2A has been found to
interact with multiple kinases including extracellular
signal-related kinase (ERK), c-Jun amino terminal
kinase (JNK), cyclin-dependent kinase-5 (CDK5),
and glycogen synthase kinase-3␤ (GSK3␤), as well
as metabotropic glutamate receptor-5 (mGluR5)
and NMDA receptors, each of which have been
implicated in AD [12, 49, 55–59]. If LCMT-1 overexpression protects against A␤-induced impairments
by altering PP2A activity, then alterations in PP2A’s
interactions with one or more of these proteins may
underlie its protective effects. Moreover, the net effect
of these alterations may also be impacted by the
complexity of the regulatory relationships among
PP2A and these targets. For example, while PP2A
dephosphorylates tau residues that are direct targets
of GSK3␤, it also activates GSK3␤ through dephosphorylation at serine 9, and evidence suggests that
GSK3␤ may, in turn, positively or negatively regulate
PP2A [59–64].
Similarly, our inability to detect a change in
demethyated PP2A levels in the LCMT-1 overexpressing mice raises the possibility that LCMT-1
transgene expression may protect against cognitive and electrophysiological impairments in Tg2576
mice via mechanisms that are independent of PP2A
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methylation. One possibility is that PME-1 or LCMT1 with may affect PP2A biogenesis or subcellular
distribution through physical association PP2A or its
subunits independent of their effect on methylation,
and this possibility is consistent with differences in
the subcellular distribution of PME-1 and LCMT-1
that have been described [65, 66]. Another possibility
is that the effects of LCMT-1 or PME-1 overexpression on A␤-related impairments may result from their
actions on targets other than PP2A. In this regard,
the phosphatases, PP4 and PP6 share a high degree
of sequence similarity to PP2A including a conserved C-terminal leucine on the catalytic subunit
that is subject to methylation by LCMT-1, and, in
the case of PP4, demethylation by PME-1 [67, 68].
If transgenic overexpression of LCMT-1 or PME1 alters the methylation levels of PP4 and/or PP6,
then the resulting changes in the activity of these
phosphatases could also contribute the effects of
LCMT-1 or PME-1 overexpression on A␤-related
impairments. Identifying the possible contributions
of different PP2A substrates and LCMT-1 targets
to the protective effects of LCMT-1 overexpression
will both further our understanding of the molecular
mechanisms underlying A␤-induced impairments,
and reveal additional targets in this pathway that may
be therapeutically relevant for AD prevention or treatment.
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